Ingen Enters Hospital and Therapy Markets With Expected Revenue Increase CEO Live Radio Broadcast Talks About These New Markets YUCAIPA, Calif., Nov 20, 2009 (GlobeNewswire via COMTEX) — Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the company is now marketing direct to the hospital and therapy respiratory markets. Ingen's CEO, Scott Sand, will discuss these new markets this coming Tuesday, November 24, 2009 at 11:34AM eastern standard time on The Money Channel's American Scene Radio with host Steve Crowley.
According to the most recent report published in June 2009 and made available on the Global Market Research Information Network, respiratory market revenues are high currently, with good potential for sales increases. As the patient population grows and respiratory diseases become more prevalent, the market has the potential for continued growth in many countries and therapeutic areas. There is a great demand for products that provide therapeutic and commercial benefits in this demanding and competitive market. The developing markets of Asia, Latin America and Europe will drive sales increases in particular.
The company is introducing its new Oxyview Nasal Cannula at the America Association of Respiratory Care (AARC) on December 5 – 7, 2009 as an exhibitor. There are 47,000 members of AARC who are hospital based clinicians, therapists and managers, and a large majority will be attending this annual meeting in San Antonio, Texas.
“Our focus has been home health care markets and this is going very smoothly with an increase in sales from home oxygen patients and oxygen providers. Our GSA application is expected to be approved in the near future, and with the growing hospital markets in respiratory care, the Oxyview Nasal Cannula will be an attractive device for hospital nursing as it has shown to save time and provide additional assurance of oxygen flow. Our near final ISO Certification expected in late December 2009 and our recent issue/publication of our patent in the People's Republic of China is in alignment with the future demand for our Oxyview Nasal Cannula in various export countries according to the most recent studies,” stated Scott Sand, Chief Executive Officer and Chairman of the Board.
About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the US, and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants, with issued patents in China and the USA, and pending patents in Japan, Canada and European Communities expected to be issued in 2010. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million US patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
2:11 pm November 23, 2009
mickymoose99
Member
posts 271
2
IGNT
Right now the is gap is 27 X 29
Bids are building @.0027 5 x 3
+ 3.57 % recovering from the dip earlier today
RSI LINE @ 46.97 and starting to rise
HIST GRAM starting to build
SLOPE is also starting to rise
With IGNT entering the hospital and therapy markets
I believe its only a matter of time before we see IGNT
Take off ,
7:04 pm November 23, 2009
mickymoose99
Member
posts 271
3
Photo Release — Ingen at Home Plate Ready to Catch Sales of $10M in 2010 and $50M in 2012 YUCAIPA, Calif., Nov 23, 2009 (GlobeNewswire via COMTEX) — Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries announced today that expected sales projections for 2010 and 2012 are on target.
The company's ISO Certification in December 2009 also allows Ingen to begin shipping product of its new Oxyview Nasal Cannula and Oxyview to China, Europe, Australia, Japan and Canada. Export sales will represent the majority of our $10M in 2010, and by 2012 reach $50M.The company's ISO consultant, Emergo Consulting Group, is assisting with both the ISO and CE Mark, as well as introducing these products to their distribution partners for export in these countries.
In addition to ISO Certification, the company expects to have in place its GSA contract with various government sectors including VA Hospitals and the Department of Defense in 3-4 weeks.
“Emergo Consulting Group will provide us with the outcome of the MEDICA exhibit in Germany, and this will be provided in a news release later this week. The Oxyview Nasal Cannula has received serious interest from institutional buyers, oxygen providers and suppliers, and patients. Sales have been made to all of these sectors in the past 2 months, and interest continues to grow,” stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
Press Release Source: Ingen Technologies, Inc. On Monday June 14, 2010, 8:15 am
Ingen Technologies, Inc. (IGNT), Manufacturer of the New SMART Nasal Cannula for the Home Care Provider Market and Hospital Market, is Featured Side-by-Side Mid and Large Cap Companies Such as Baxter (BAX) at the Alpha-1 19th Annual National Education Conference
YUCAIPA, Calif., June 14, 2010 (GLOBE NEWSWIRE) — Ingen Technologies, Inc. (Pink Sheets:IGNT – News), a medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S. and $8 billion globally, unveiled their new SMART Nasal Cannula in Orlando-Florida last week at the Alpha-1 19th Annual National Education Conference.
The Alpha-1 Association is a member-based not-for-profit organization dedicated to identifying those affected by Alpha-1 Antitrypsin Deficiency (Alpha-1) and to improve the quality of their lives through support, education, advocacy and to encourage participation in research. Alpha-1-Antitrypsin Deficiency (Alpha-1) is a genetic disorder that can cause liver and lung disease in children and adults.
“We were very pleased to be an exhibitor and sponsor at this year's conference for Alpha-1. There are hundreds of patient members of the Alpha-1 Association, and many of them attended the conference, along with clinicians and physicians from around the globe. Our new SMART Nasal Cannula was featured and well accepted by the attendees. It is our goal to pick up the pace in supporting the various associations that support patients who require home oxygen therapy and the use of our products,” stated Scott R. Sand, CEO and Chairman of the Board.
Ingen is an ISO Certified medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and a successful registration with the Food & Drug Administration. The company is establishing domestic and global distribution with manufacturer representative organizations, and OEM partners. In 2009 the SMART Nasal Cannula using Oxyview Technology was introduced as the world's first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced its new INGEN Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
Press Release Source: Ingen Technologies, Inc. On Friday June 18, 2010, 5:00 pm EDT
YUCAIPA, Calif., June 18, 2010 (GLOBE NEWSWIRE) — Ingen Technologies, Inc. (Pink Sheets:IGNT – News), a medical device manufacturer with an emerging new medical product line for the $8B respiratory market, announced today that the company has officially accepted to be an exhibitor and sponsor at the upcoming Medtrade conference in Atlanta, Georgia from November 15-18, 2010 at the Georgia World Congress Center.
The Home Medical Equipment industry is constantly evolving, but one thing remains the same — the demand for the latest products and technology will be at Medtrade where thousands of qualified attendees will be there to buy the products and services that are right for their customers, and that will ensure the success of their business. Ingen will introduce the new IngenThermo drug product, as well as their Oxyview product line and SMART Nasal Cannula.
The company plans to seize this great opportunity to take advantage of all Medtrade has to offer. The company will showcase its products and services, and create new alliances.
“We are focused on product sales and marketing. Our tradeshow attendance will double this year in order to brand our products. We look forward to a very successful and prosperous fiscal year 2010,” stated Scott R. Sand, CEO and Chairman of the Board.
Ingen is an ISO Certified medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and a successful registration with the Food & Drug Administration. The company is establishing domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the SMART Nasal Cannula using Oxyview Technology was introduced as the world's first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced its new INGEN Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
10:17 am June 21, 2010
mickymoose99
Member
posts 271
6
Ingen Scheduled for Medtrade-AtlantaManagement and Consulting Partners Pushing Hard to Meet $11M Projected Sales
Press Release Source: Ingen Technologies, Inc. On Friday June 18, 2010, 5:00 pm EDT
YUCAIPA, Calif., June 18, 2010 (GLOBE NEWSWIRE) — Ingen Technologies, Inc. (Pink Sheets:IGNT – News), a medical device manufacturer with an emerging new medical product line for the $8B respiratory market, announced today that the company has officially accepted to be an exhibitor and sponsor at the upcoming Medtrade conference in Atlanta, Georgia from November 15-18, 2010 at the Georgia World Congress Center.
The Home Medical Equipment industry is constantly evolving, but one thing remains the same — the demand for the latest products and technology will be at Medtrade where thousands of qualified attendees will be there to buy the products and services that are right for their customers, and that will ensure the success of their business. Ingen will introduce the new IngenThermo drug product, as well as their Oxyview product line and SMART Nasal Cannula.
The company plans to seize this great opportunity to take advantage of all Medtrade has to offer. The company will showcase its products and services, and create new alliances.
“We are focused on product sales and marketing. Our tradeshow attendance will double this year in order to brand our products. We look forward to a very successful and prosperous fiscal year 2010,” stated Scott R. Sand, CEO and Chairman of the Board.
Ingen is an ISO Certified medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and a successful registration with the Food & Drug Administration. The company is establishing domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the SMART Nasal Cannula using Oxyview Technology was introduced as the world's first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced its new INGEN Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
Forums
